Crestor and Dyslipidaemia - a phase IV clinical study of FDA data

Summary:

Dyslipidaemia is reported as a side effect among people who take Crestor (rosuvastatin calcium), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Aspirin, and have Hiv infection.

The phase IV clinical study analyzes which people have Dyslipidaemia when taking Crestor. It is created by eHealthMe based on reports of 143,349 people who have side effects when taking Crestor from the FDA, and is updated regularly.

What is Crestor?

Crestor has active ingredients of rosuvastatin calcium. It is often used in high blood cholesterol. eHealthMe is studying from 149,761 Crestor users. Check the latest studies of Crestor.

What is Dyslipidaemia?

Dyslipidaemia (abnormal amount of lipids) is found to be associated with 842 drugs and 711 conditions by eHealthMe. Check the latest studies of Dyslipidaemia.

On Jul, 13, 2026

143,349 people reported to have side effects when taking Crestor.
Among them, 242 people (0.17%) have Dyslipidaemia.

Among these 242 people:

* Approximation only. Some reports may have incomplete information.

Do you take Crestor and have Dyslipidaemia?

- Check whether Dyslipidaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Crestor:

Crestor (149,761 reports)

Dyslipidaemia treatments and more:

Dyslipidaemia (42,009 reports)

How severe was Dyslipidaemia and when was it recovered:

Dyslipidaemia in Crestor

Expand to all the drugs that have ingredients of rosuvastatin calcium:

Dyslipidaemia and drugs with ingredients of rosuvastatin calcium (585 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Crestor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dyslipidaemia:

Dyslipidaemia (842 drugs)

Browse all the conditions that are associated with Dyslipidaemia:

Dyslipidaemia (711 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rosuvastatin calcium (the active ingredients of Crestor) and Crestor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.